Clinical trials: Stomach Diseases
Esophageal Cancer, GastroEsophageal Cancer
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with…
- Conditions
- Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
- Trial name
- ZOLA (NCT07780968)
- Testing
- Zanidatamab
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Jazz Pharmaceuticals
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treated with 8 cycles of the FLOT scheme (up to 12 cycles if the response is…
- Trial name
- FLOT3 (NCT00849615)
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 252 people
- Sponsor
- Krankenhaus Nordwest
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Laryngomalacia, Gastro Esophageal Reflux
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the…
- Trial name
- NCT04614974
- Testing
- Famotidine, Speech Language Therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Reema Padia
Esophageal Cancer, Gastric Cancer
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
The aim of this project is to study the presence of cancer-associated adipocytes in oesogastric cancers and their possible links with myosteatosis.
- Conditions
- Esophageal Cancer, Gastric Cancer, Myopenia, Adipose Tissue Tumor
- Trial name
- NCT06419244
- Testing
- Myosteatosis
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel.
- Trial name
- NCT06513104
- Testing
- NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Novo Nordisk A/S
Barrett Esophagus, Esophageal Cancer
EsophaCap for the Detection of Early Esophageal Carcinoma
This study is to identify potential biomarkers for the early detection of Barrett's Esophagus, esophageal carcinoma (both adenocarcinoma and squamous cell carcinoma), and gastric cancer via sponge cytology.
- Conditions
- Barrett Esophagus, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT04214119
- Where
- 2 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Gastric Cancer, Peritoneal Carcinomatosis
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
Rationale: For patients with peritoneal metastases of gastric origin, there is no consensus on the optimal treatment strategy. Several Asian and Western studies demonstrated hyperthermic intraperitoneal chemotherapy (HIPEC) and…
- Conditions
- Gastric Cancer, Peritoneal Carcinomatosis, HIPEC
- Trial name
- CISCA (NCT03150628)
- Testing
- Perioperative chemotherapy, Cytoreduction, HIPEC
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- Richard van Hillegersberg
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor…
- Conditions
- Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
- Trial name
- NCT07554521
- Testing
- Tislelizumab, Capecitabine, 5-fluorouracil (5-FU)
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Gastric Cancer
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
To evaluate efficacy and safety of Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) in resectable locally advanced gastric cancer.
- Trial name
- NCT06054906
- Testing
- sintilimab+metronomic PLOF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huashan Hospital
Oncology, Metabolic Disease
Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients
The metabolic effect of oncometabolic surgery (long limb Roux-en Y reconstruction) for early gastric cancer patients has been revealed in a few pilot studies.
- Conditions
- Oncology, Metabolic Disease, Gastric Cancer
- Trial name
- ONCOMETAB (NCT03067012)
- Testing
- Oncometabolic reconstruction
- Volunteers
- 20 people
- Sponsor
- Seoul National University Bundang Hospital
Gastro Esophageal Reflux
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Gastro-oesophageal reflux disease (GORD) is a chronic condition with symptoms arising secondary to the reflux of stomach contents (Vakil et al., 2006).
- Trial name
- NCT04268719
- Testing
- wireless pH capsule recording
- Where
- United Kingdom
- Volunteers
- 76 people
- Sponsor
- King's College Hospital NHS Trust
Adenocarcinoma of the Stomach
Early Oral Feeding After Total Gastrectomy for Cancer
The aim of this study is to evaluate the possibility of shortening postoperative hospital stay after gastrectomy by early oral feeding as a component of an enhanced recovery protocol (ERAS).
- Trial name
- NCT01962519
- Testing
- Early oral feeding
- Where
- Poland
- Volunteers
- 112 people
- Sponsor
- Jagiellonian University
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
Type II Diabetes in Subjects BMI 27 to 32
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2).
- Trial name
- NCT02041234
- Testing
- Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Khoo Teck Puat Hospital
Lung Cancer, Breast Cancer
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps.
- Conditions
- Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer
- Trial name
- SkinHealth (NCT05878964)
- Testing
- EQ-5D-5L questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
- Where
- Italy
- Volunteers
- 420 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gastro-esophageal Reflux Disease
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD).
- Trial name
- NCT02114216
- Testing
- endoscopic mucosal biopsy
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Gastroesophageal Reflux
The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population
The purpose of this study is to evaluate the efficacy of proton pump inhibitor for the treatment of non-erosive reflux disease (NERD) in Chinese population.
- Trial name
- NCT00516971
- Testing
- Esomeprazole 20mg once daily
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hospital Authority, Hong Kong
Solid Tumor, Gastric Cancer
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT04511871
- Testing
- CCT303-406
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.